MERCK SHARP & DOHME CORP: Drug Recall
Recall #D-0093-2022 · 10/19/2021
Class I: Dangerous
Recall Details
- Recall Number
- D-0093-2022
- Classification
- Class I
- Product Type
- Drug
- Recalling Firm
- MERCK SHARP & DOHME CORP
- Status
- Terminated
- Date Initiated
- 10/19/2021
- Location
- Whitehouse Station, NJ, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 76,163 vials
Reason for Recall
Presence of Particulate Matter: Identified as Glass Particles
Product Description
Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only. Manuf. for: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Manuf. by: Baxter Pharmaceuticals LLC., Bloomington, IN 47403, USA, NDC: 67919-011-01
Distribution Pattern
Nationwide within the United States
Other Recalls by MERCK SHARP & DOHME CORP
- Class II: Risk 03/31/2022
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.